Wall Street analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to post earnings per share (EPS) of $0.58 for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.56 to $0.61. Teva Pharmaceutical Industries reported earnings of $0.55 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The company is scheduled to issue its next quarterly earnings report on Wednesday, August 4th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.64 per share for the current year, with EPS estimates ranging from $2.55 to $2.68. For the next financial year, analysts forecast that the company will report earnings of $2.81 per share, with EPS estimates ranging from $2.65 to $3.03. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, April 28th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.08. The firm had revenue of $3.98 billion for the quarter, compared to analyst estimates of $4.04 billion. Teva Pharmaceutical Industries had a negative net margin of 24.45% and a positive return on equity of 21.65%. The company’s revenue for the quarter was down 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.76 EPS.
NYSE:TEVA opened at $11.53 on Friday. Teva Pharmaceutical Industries has a one year low of $8.44 and a one year high of $13.30. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.03 and a quick ratio of 0.66. The business’s 50-day simple moving average is $10.63. The company has a market capitalization of $12.59 billion, a price-to-earnings ratio of -3.18, a P/E/G ratio of 0.89 and a beta of 1.46.
In other news, VP David Matthew Stark sold 37,884 shares of the firm’s stock in a transaction dated Tuesday, May 11th. The shares were sold at an average price of $10.22, for a total value of $387,174.48. Following the sale, the vice president now directly owns 40,858 shares in the company, valued at approximately $417,568.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Eric Drape sold 40,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 21st. The stock was sold at an average price of $11.01, for a total transaction of $440,400.00. Following the completion of the sale, the vice president now owns 33,128 shares of the company’s stock, valued at $364,739.28. The disclosure for this sale can be found here. Insiders sold a total of 205,128 shares of company stock worth $2,255,252 in the last ninety days. 0.56% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in TEVA. Ayalon Holdings Ltd. purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth approximately $26,000. Freedman Financial Associates Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $38,000. Safeguard Investment Advisory Group LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $42,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at approximately $57,000. Finally, Carolina Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 13,261.7% during the 1st quarter. Carolina Wealth Advisors LLC now owns 6,280 shares of the company’s stock valued at $72,000 after purchasing an additional 6,233 shares in the last quarter. Institutional investors own 52.60% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.